Lung cancer hyperthermia via ultrasound and/or convection with perfiuorochemical liquids

• US 5,158,536 A
• Filed: 03/19/1990
• Issued: 10/27/1992
• Est. Priority Date: 08/28/1989
• Status: Expired due to Term

• Current Assignee: Temple University of The Commonwealth System of Higher Education
• Original Assignee: BioPulmonics, Inc. (Alliance Pharmaceutical Corporation), Temple University of The Commonwealth System of Higher Education
• Inventors: Sekins, K. Michael, Wolfson, Marla R., Shaffer, Thomas H.
• Primary Examiner(s): Pellegrino, Steven C.
• Assistant Examiner(s): Rafa, Michael
• Application Number:
  US07/495,817
• Time in Patent Office: 953 Days
• Field of Search: 604/20, 604/22, 604/49, 128/598
• US Class Current: 604/20
• CPC Class Codes: A61B 2017/22054 with two balloons
• CPC Class Codes: A61B 2018/00011 with fluids
• CPC Class Codes: A61F 2007/0054 with a closed fluid circuit, e.g. hot water
• CPC Class Codes: A61F 7/123 using a flexible balloon containing the thermal element
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61M 15/00 Inhalators drug delivery in endotracheal tubes A61M16/04
• CPC Class Codes: A61M 16/0006 with means for creating vibrations in patients' airways
• CPC Class Codes: A61M 16/0404 with means for selective or partial lung respiration
• CPC Class Codes: A61M 16/0438 Liquid-filled
• CPC Class Codes: A61M 16/0443 Special cuff-wall materials A61M16/0481, A61M16/0422 take precedence
• CPC Class Codes: A61M 16/0454 Redundant cuffs
• CPC Class Codes: A61M 16/0459 one cuff behind another
• CPC Class Codes: A61M 16/0463 combined with suction tubes, catheters or the like; Outside connections
• CPC Class Codes: A61M 16/0479 above the cuff, e.g. giving access to the upper trachea
• CPC Class Codes: A61M 16/0486 Multi-lumen tracheal tubes
• CPC Class Codes: A61M 2202/0468 non-physiological
• CPC Class Codes: A61M 2202/0476 Oxygenated solutions
• CPC Class Codes: A61M 2205/3368 Temperature
• CPC Class Codes: A61N 7/022 intracavitary
• CPC Class Codes: B06B 1/0633 Cylindrical array

Abstract

A hyperthermic treatment of lung cancer, by temporarily filling with a liquid medium preselected pulmonary air passages adjoining pulmonary tissues containing malignant cells, circulating exogenously heated liquid medium at from about 41° to ab

This invention was made with government support under Small Business Innovation Research Program Grant No. 1 R43 CA48611-01 awarded by the Public Health Service, Department of Health and Human Services. The government has certain rights in the invention.

Claims

1. A hyperthermic treatment of lung cancer, comprising the steps of:

temporarily filling with a liquid medium preselected pulmonary air passages adjoining pulmonary tissues comprising malignant cells,

heating the adjoining pulmonary tissues comprising the malignant cells to a temperature in the range of from about 41°

to about 50°

C. for a period of time by transmitting ultrasound through the liquid-filled pulmonary air passages, and

thereafter removing the liquid medium from the pulmonary air passages of the patient.

2. The hyperthermic treatment of claim 1, wherein the temperature is in the range of from about 42°

to about 45°

C.

3. The hyperthermic treatment of claim 1, wherein the liquid medium is a perfluorochemical.

4. The hyperthermic treatment of claim 3, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 400 to about 500.

5. The hyperthermic treatment of claim 4, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 400 to about 460.

6. The hyperthermic treatment of claim 5, wherein the perfluorochemical is characterized by an average molecular weight in the range of from about 420 to about 460.

7. The hyperthermic treatment of claim 3, wherein the perfluorochemical is characterized by having:

viscosity less than about 5 CP at 25°

C.,

density at less than about 2.0 g/cm³ at 25°

C.,

boiling point greater than about 75°

C.,

vapor pressure in the range of from about 25 Torr to about 100 Torr,

acoustic impedance in the range of from about 0.8 to about 1.6 MegaRayls at 37°

C.,

acoustic attenuation less than about 1.2 dB/cm at 1.0 MHz, 45°

C., and an acoustic intensity of about 3 W/cm².

8. The hyperthermic treatment of claim 7, wherein the perfluorochemical is characterized by O₂ solubility greater than about 40 ml/100 ml.

9. The hyperthermic treatment of claim 5, wherein the perfluorochemical is selected from among FC-75, RM-101, and perfluorodecalin.

10. The hyperthermic treatment of claim 3, wherein the ultrasound is in the frequency range of from about 250 KHz to about 3 MHz.

11. The hyperthermic treatment of claim 10, wherein the ultrasound is in the frequency range of from about 500 KHz to about 2 MHz.

12. The hyperthermic treatment of claim 10, wherein the ultrasound is in the frequency range of from about 250 KHz to about 1.5 MHz.

13. The hyperthermic treatment of claim 1, wherein the liquid medium is physiological saline.

14. The hyperthermic treatment of claim 13, wherein the ultrasound is in the frequency range of from about 250 KHz to about 3 MHz.

15. The hyperthermic treatment of claim 14, wherein the ultrasound is in the frequency range of from about 500 KHz to about 3 MHz.

16. The hyperthermic treatment of claim 15, wherein the ultrasound is in the frequency range of from about 750 KHz to about 3 MHz.

17. The hyperthermic treatment of claim 1, wherein the ultrasound is produced by a transducer disposed within the liquid-filled pulmonary air passages.

18. The hyperthermic treatment of claim 1, wherein the ultrasound is produced by a transducer disposed exogenous to the liquid-filled pulmonary air passages.

19. The hyperthermic treatment of claim 18, wherein the ultrasound is transmitted through an intercostal space of the patient.

20. The hyperthermic treatment of claim 1, wherein the filling of the liquid-filled pulmonary air passages is monitored by diagnostic ultrasonic imaging.

21. The hyperthermic treatment of claim 3, wherein the perfluorochemical is degassed during the filling step.

22. The hyperthermic treatment of claim 21, wherein the perfluorochemical is substantially degassed at least during the filling step.

23. The hyperthermic treatment of claim 1, further comprising, during the heating step, irradiating the malignant cells with ionizing radiation.

24. The hyperthermic treatment of claim 23, further comprising the step of oxygenating the liquid medium in the liquid-filled pulmonary air passages.

25. The hyperthermic treatment of claim 24, wherein ultrasound in the frequency range of from about 2 MHz to about 3 MHz is transmitted through the pulmonary air passages filled with a perfluorochemical oxygenated to no more than about 75 percent saturation.

26. The hyperthermic treatment of claim 24, wherein ultrasound in the frequency range of from about 250 KHz to about 1.5 MHz is transmitted through the pulmonary air passages filled with a perfluorochemical oxygenated to no more than about 50 percent saturation.

27. The hyperthermic treatment of claim 1, wherein the liquid medium comprises a therapeutic agent.

28. The hyperthermic treatment of claim 1, further comprising the step of introducing a chemotherapeutic agent into the liquid-filled pulmonary air passages.

29. The hyperthermic treatment of claim 1, wherein the liquid medium is circulated during the heating step between the liquid-filled air passages and an exogenous reservoir.